|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Methoxsalen belongs to the group of medicines called psoralens. It is used along with ultraviolet light (found in sunlight and some special lamps) in a treatment called PUVA to treat vitiligo, a disease in which skin color is lost, and psoriasis, a skin condition associated with red and scaly patches. Methoxsalen is also used with ultraviolet light in the treatment of white blood cells. This treatment is called photopheresis and is used to treat the skin problems associated with mycosis fungoides, which is a type of lymphoma. Methoxsalen may also be used for other conditions as determined by your doctor. methoxsalen is available only with your doctor’s prescription. Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in the product labeling, methoxsalen is used in certain patients with the following medical conditions: Alopecia areata. Atopic dermatitis. Eczema. Lichen planus. Skin that is abnormally sensitive to sunlight.
Diseases associated with light sensitivity e.g. porphyria. Aphakia, melanoma or a history of melanoma, invasive squamous cell carcinoma. PUVA therapy in children.
Nausea, insomnia, depression, nervousness. Photochemotherapy or PUVA may cause pruritus, mild transient erythema, oedema, dizziness, headache, vesiculation, bulla formation, acneiform eruption, severe skin pain; pigmentation alterations of skin or nails, onycholysis. Hypersensitivity reactions e.g. fever, bronchoconstriction, contact dermatitis. Potentially Fatal: Increased risk of skin cancers e.g. squamous cell carcinoma, basal cell carcinoma, malignant melanoma. Isolated reports of leukaemia.
Additive effects with drugs known to cause photosensitisation e.g. anthralin, coal tar or derivatives, griseofulvin, phenothiazines, nalidixic acid, sulfonamides., tetracyclines and thiazide diuretics. May increase the levels/effects of aminophylline, fluvoxamine, mexiletine, mirtazapine, ropinirole, theophylline, trifluoperazine, dexmedetomidine and ifosfamide.
Certain photosensitivity disorders. Hepatic impairment. Do not sunbathe for 24 hr before and 48 hr after PUVA treatment. Avoid exposure to sunlight for at least 8 hr after admin and patient should wear wrap-around UVA absorbing glasses for 24 hr after admin. Shield male genitalia during PUVA therapy unless specific treatment is required. Perform ophthalmic exam prior to therapy and at regular intervals thereafter, especially in those at increased risk of cataracts. Regularly examine patients for signs of premalignant or malignant skin lesions. Pregnancy and lactation.
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr. Hani Najjar
Dr. Talal Sabouni
Dr. Faisal Dibsi
Dr. Tahsin Martini
Yaser Habrawi , F.R.C.S.Ed
Dr . Dirar Abboud
Samir Moussa M.D.
Dr. Samer Al-Jneidy